Joshua Davis
@Josh_S_Davis
Followers
4K
Following
765
Media
106
Statuses
2K
Infectious Diseases physician, clinical researcher - clinical trials, SAB, PJI, sepsis, viral hep. #IDTwitter @snap_trial @ASCOT_trial @ASIDANZ
Newcastle, Darwin (Australia)
Joined March 2015
Presented at #LIVES2025: In the SuDDICU trial of patients undergoing mechanical ventilation in the intensive care unit, selective decontamination of the digestive tract did not result in a lower incidence of in-hospital death than standard care alone. Full trial results:
1
21
91
What’s in a name?” Even microbes carry stories. @CMIComms is launching a new series exploring the people behind eponymous organisms—those whose names live on through microbes like Escherichia or Pasteurella. Open call for submissions @Josh_S_Davis
https://t.co/JpGcd41fvd
1
9
27
Those interested in adaptive platform trials might be interested in this recent chat @syctong and I had with @TheLancetInfDis podcast https://t.co/uXbeCH4mye
0
3
5
Due to the USG Shutdown, I wasn’t able to attend or present @IDWeekmtg. I was supposed to give the talk on top viral studies that will impact your practice. Here are the papers I was going to highlight: See next tweets
1
12
55
How long do labs need to incubate #PJI specimens for? Clinicians and some guidelines want long (10-14 days) BUT with modern media and processes, this is probably not needed. See our new paper here https://t.co/TuoytsfEqR
@victoriajordann #IDTwitter #orthotwitter
0
0
4
Probably the paper I am most proud of. The JAMA IM paper that suggested cefepime was superior is unfortunately flawed in its design. There is no evidence from that study that cefepime is better. Clinicians should treat empirical IV analyses carefully! They are V prone to bias.
Does piperacillin-tazobactam increase mortality risk compared to cefepime? Collider bias and the importance of assumptions in instrumental variable analyses ✅ Just Accepted 🔗 https://t.co/jes8yQa3Yc
1
5
40
Do you know where the recommendation of adjunctive therapy for E.faecalis IE came from? A case series published in 1954 (with numerous limitations) Time for a well-designed RCT of adjunctive versus monotherapy indeed
We do love a good time travel! The answers may surprise you..... A deep dive into the origins of adjunctive therapy for E. fecalis IE
0
10
30
🧵 “ANA Positive ≠ Lupus: The Art of Interpreting Autoantibodies” ANA positivity is one of the most misunderstood findings in medicine. Here’s how to approach an ANA report systematically, clinically, and with confidence. 👇 #Rheumatology #ANA #Autoimmunity #MedEd @DrAkhilX
11
315
994
Fun to see this in print. This was a hard project because we had to build an EMR interface (had never done before) and then was run during the pandemic! Congratulations @DrEmilyMcD we can reduce potentially inappropriate medications in long term care! https://t.co/WUixHyYmYo
jamanetwork.com
This stepped-wedge cluster randomized trial of long-term care home residents assesses the efficacy of an evidence-based electronic decision support tool for deprescribing potentially inappropriate...
4
7
31
@snap_trial is the little engine that could! Congratulations on passing 4500 participants @syctong @Josh_S_Davis
4
4
33
In memory of professor Rinaldo Bellomo: A giant of intensive care medi...
2
20
41
Selective digestive tract decontamination in ICUs: Life saver or recipe for disaster? By @Josh_S_Davis and @peripatetical
cmi-comms.org
‘Selective digestive tract decontamination’ (SDD) refers to the use of antibiotics to decrease bacterial load in the gut with the intention of reducing the risk of pneumonia (from microaspiration)...
0
2
3
Check out this fun collaboration between #breakpoints and #communicable podcasts about the first SNAP trial results. @syctong @SIDPharm
https://t.co/HB0VUIPB15
podcasts.apple.com
Podcast Episode · Breakpoints · 05/04/2025 · 1h 11m
0
7
24
For all those who wondering …are all cl(ox) created equal?? 🕰️
🆕💫 Systematic Review and Meta-Analysis @CMIJournal @ConnorProsty @DrToddLee @DrEmilyMcD @syctong 30 observational studies( SNAP & CloCeBa not included) N: 3869 Cefazolin versus Antistaphylococcal Penicillins for the Treatment of MSSA Bacteremia #idxposts
https://t.co/R01Dm8E2op
0
2
10
Just thinking that Ortho Bro would be pretty darned excited that cefazolin looked pretty super in the largest S aureus bactermia RCT ever conducted #ESCMIDGlobal "Super ancef" confirmed. No administrative trickery involved. @snap_trial @Josh_S_Davis
@syctong @DGlaucomflecken
2
3
38
Oh @snap_trial. (Flu)cloxacillin was just assassinated. When it comes to MSSA, cefazolin was shown to be non-inferior in terms of mortality and superior in terms of AKI. (Flu)cloxacillin clearly shown to be nephotoxic. Major cudos to @syctong, Dr. Joshua Davis, and colleagues.
4
20
56
Taking a break from talking about #SNAPtrial to work on a new collaboration #IDSky #ESCMIDglobal
@syctong
2
0
25
Agree. My take: - Did we use cefazoline before SNAP? Yes, but not in severe or more complex cases (worried about the inoculum effect issue) - Will we use it now in all cases? Yes. So, practice-changing for us. Well done, @Josh_S_Davis @syctong and team
@BradSpellberg We should not change or base our practice on observational studies. They are often wrong. In this case they were not, but the only was of knowing that for sure is to remove bias by doing big RCTs
0
6
22
The most anticipated RCT in ID 🔥SNAP RCT🔥The largest RCT 2 date in SA bactermia N:1341 Cefazolin Vs ASPs ((flu)cloxacillin) for MSSA bacteremia Cefazolin is non-inferior (90d mortality)& less AKI than ASPs A practice-changer RCT that must change the guidelines #ESCMIDGlobal
17% vs 15% mortality, non inferior, at 90 days. Kaplan Meir and differences in mortality at other time points are below. Big difference in AKI 19.1 vs 13.7 %. Flucox vs cefazolin.
12
90
250
@snap_trial keeps on chugging. Looking forward to the presentation at ESMID in ~2 weeks. Too bad I am on call and can't attend. Someone record it for me! @syctong @Josh_S_Davis
1
1
16